Recent investigations have converged on the intersection of GLP-1|GIP|glucagon receptor agonist therapies and DA neurotransmission. While GCGR agonists are commonly employed for managing type 2 T2DM, their unexpected impacts on reward circuits, specifically influenced by dopamine networks, are attracting significant interest. This report details… Read More